UPDATE: Canaccord Genuity Reiterates Buy Rating, Lowers PT on Amarin Corporation
In a report published Friday, Canaccord Genuity reiterated its Buy rating on Amarin Corporation (NASDAQ: AMRN), but lowered its price target from $26.00 to $19.00.
Canaccord Genuity noted, “Reiterate BUY, lowering target to $19; maintain positive view on Vascepa commercial, partnering potential while acknowledging increased commercial risk. We continue to expect business development talks to intensify and Vascepa to receive NCE (five-year exclusivity). Our $19 target is based on a sum-of-the-parts analysis, combining a DCF of high triglyceride sales and pNPV of mixed dyslipidemia sales.”
Amarin Corporation closed on Thursday at $11.95.
Latest Ratings for AMRN
|Mar 2015||HC Wainwright||Upgrades||Buy|
|Feb 2015||SunTrust Robinson Humphrey||Upgrades||Neutral||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.